Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

But the LillyDirect Zepbound offer is for vials that patients ... the vials compared to a list price of $1,086.37 per monthly injector pen. Wegovy’s maker, Novo Nordisk, is charging $499 per ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

The lower-cost Zepbound for self-pay patients on LillyDirect comes in single-dose vials, instead of the more expensive pre-loaded pens for injection. Lilly’s overall growth primarily is driven ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Weight loss medications like Wegovy and Zepbound can be effective but may pose risks for older adults, including muscle loss and bone density decline.